Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage.

Aglaia ChalkiaOliver FlossmannRachel JonesJagdish Ramachandran NairThomas SimpsonRona SmithLisa WillcocksDavid Jayne

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

We report the use of avacopan as a component of the treatment for pulmonary haemorrhage with hypoxia in AAV. Despite the life-threatening presentations all patients recovered, but attribution of the positive outcomes to avacopan is limited by the concomitant therapies and retrospective observational design.

Keyphrases

end stage renal disease
pulmonary hypertension
ejection fraction
newly diagnosed
chronic kidney disease
cross sectional
prognostic factors
type diabetes
patient reported outcomes
gene therapy
insulin resistance
replacement therapy
smoking cessation